- £111.64m
- £80.36m
- £62.73m
- 72
- 46
- 14
- 36
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.07 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -7.03% | ||
| Dividend Yield (f) | 1.51% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.5 | ||
| Price to Tang. Book | 2.86 | ||
| Price to Free Cashflow | 14.17 | ||
| Price to Sales | 1.78 | ||
| EV to EBITDA | 4.9 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 22.56% | ||
| Return on Equity | 26.97% | ||
| Operating Margin | 20.5% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 20.6 | 36.86 | 48.48 | 56.04 | 62.73 | 72.81 | 80.59 | 79.44% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +320 | -35.34 | -21.51 | +36.3 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
hVIVO plc is a United Kingdom-based specialist early-stage drug development contract research organization (CRO) and human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base. It specializes in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its quarantine facility. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand. The Company, through its subsidiary, operates an approximately 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. It also offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Company also provides industry-standard, temperature-controlled storage solutions for biological and clinical materials.
Directors
- Cathal Friel CHM (56)
- Leo Toole CFO (48)
- Brendan Buckley NED (71)
- Elaine Sullivan NED (60)
- Yamin Mohammed Khan NID (52)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 2nd, 2011
- Public Since
- December 14th, 2012
- No. of Employees
- 301
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 687,014,088
- Address
- 42 New Road, LONDON, E1 2AX
- Web
- https://hvivo.com/
- Phone
- +44 2890737900
- Auditors
- Gravita Audit Limited
Latest News for HVO
Upcoming Events for HVO
Dividend For HVO.L - 0.2000 GBX
hVIVO PLC Annual Shareholders Meeting
Half Year 2025 hVIVO PLC Earnings Release
Similar to HVO
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 21:10 UTC, shares in hVIVO are trading at 16.25p. This share price information is delayed by 15 minutes.
Shares in hVIVO last closed at 16.25p and the price had moved by -41.12% over the past 365 days. In terms of relative price strength the hVIVO share price has underperformed the FTSE All Share Index by -43.44% over the past year.
The overall consensus recommendation for hVIVO is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe hVIVO dividend yield is 1.23% based on the trailing twelve month period.
Last year, hVIVO paid a total dividend of £0.00, and it currently has a trailing dividend yield of 1.23%.Looking ahead, shares in hVIVO are due to go ex-dividend on 2025-05-15 and the next dividend pay date is 2025-06-11.
hVIVO are due to go ex-dividend on 2025-05-15 and the next dividend pay date is 2025-06-11. The historic dividend yield on hVIVO shares is currently 1.23%.
To buy shares in hVIVO you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 16.25p, shares in hVIVO had a market capitalisation of £111.64m.
Here are the trading details for hVIVO:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: HVO
Based on an overall assessment of its quality, value and momentum hVIVO is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in hVIVO is 31.00p. That is 90.78% above the last closing price of 16.25p.
Analysts covering hVIVO currently have a consensus Earnings Per Share (EPS) forecast of £0.01 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like hVIVO. Over the past six months, its share price has underperformed the FTSE All Share Index by -42.57%.
As of the last closing price of 16.25p, shares in hVIVO were trading -29.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The hVIVO PE ratio based on its reported earnings over the past 12 months is 12.07. The shares last closed at 16.25p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
hVIVO's management team is headed by:
- Cathal Friel - CHM
- Leo Toole - CFO
- Brendan Buckley - NED
- Elaine Sullivan - NED
- Yamin Mohammed Khan - NID